Ipatasertib is a novel, potent, selective small-molecule inhibitor of Akt that has been tested in combination with atezolizumab, the mAb against PD-L1 in solid tumors, including glioblastoma, with the aims of depleting the tumor microenvironment of suppressive immune cells with Akt inhibition and of making tumor cells more responsive to immune checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.